RGTLF (Argent Biopharma) Total Stockholders Equity: $-5.61 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Argent Biopharma Total Stockholders Equity?

Argent Biopharma RGTLF Total Stockholders Equity is $-5.61 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Argent Biopharma's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-5.61 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Argent Biopharma's Book Value per Share for the quarter that ended in Dec. 2025 was $-0.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Argent Biopharma's Debt-to-Equity for the quarter that ended in Dec. 2025 was -1.06.

Argent Biopharma  (OTCPK:RGTLF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Argent Biopharma's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.611-0)/83.385
=-0.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Argent Biopharma's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.013 + 0.908) / -5.611
=-1.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Total Stockholders Equity Related Terms

Argent Biopharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Total Stockholders Equity Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.57 7.89 -5.04 -3.42 -5.62

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.91 -3.42 -6.89 -5.62 -5.61
What does a Total Stockholders Equity of $-5.61 Mil mean?
Argent Biopharma (RGTLF) has a Total Stockholders Equity of $-5.61 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Argent Biopharma and its competitors.
Is Argent Biopharma's Total Stockholders Equity too high?
Argent Biopharma's current Total Stockholders Equity is $-5.61 Mil.
How does Argent Biopharma's Total Stockholders Equity compare to ZTS and UTHR?
Argent Biopharma's Total Stockholders Equity of $-5.61 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Argent Biopharma and its competitors. Argent Biopharma's current Total Stockholders Equity is $-5.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Total Stockholders Equity is $-5.61 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Total Stockholders Equity is $-5.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.